Efalizumab in Psoriasis: Our Experience with 11 Patients~!2010-01-28~!2010-05-10~!2010-06-11~!

Efalizumab in Psoriasis: Our Experience with 11 Patients

This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the qualit...

DAC S - 87 . 4198 Thu 11 . 05 . 06

02 Saper 05-11

1257 In 1916, Baron Constantin von Economo, a Viennese neurologist, began to see patients with a new type of encephalitis that specifically attacked regions of the brain that regulate sleep and wakefulness. This disorder, which was eventually called encephalitis lethargica or von Economo’s sleeping sickness, swept through Europe and North America during the second decade of the twentieth centur...

Efalizumab-associated papular psoriasis.

BACKGROUND Efalizumab is a human anti-CD11a monoclonal antibody used in the treatment of patients with moderate to severe plaque psoriasis. Some of the patients develop new papular lesions during treatment, which are predominantly located in the flexural regions. OBSERVATION Four patients with recalcitrant psoriasis undergoing treatment with efalizumab presented with erythematous, partly scal...

Our experience with etanercept in the treatment of psoriasis.

Psoriasis is a chronic inflammatory disorder that usually requires long-term control. Etanercept has been shown to be effective in this disease. The efficacy and safety of etanercept were assessed in patients with psoriasis. In this 16-week open clinical trial, 29 patients with clinically stable psoriasis and psoriatic arthritis received etanercept (25 mg twice weekly) subcutaneously. All patie...